1
|
Chen H, Zhu MZ, Wang XT, Ai M, Li SS, Wan MY, Wang PY, Cai WW, Hou B, Xu F, Lang F, Qiu LY, Zhou YT. 1,25(OH) 2 D 3 inhibits Lewis lung cancer cell migration via NHE1-sensitive metabolic reprograming. IUBMB Life 2024; 76:182-199. [PMID: 37921568 DOI: 10.1002/iub.2789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Accepted: 09/28/2023] [Indexed: 11/04/2023]
Abstract
High prevalence and metastasis rates are characteristics of lung cancer. Glycolysis provides energy for the development and metastasis of cancer cells. The 1,25-dihydroxy vitamin D3 (1,25(OH)2 D3 ) has been linked to reducing cancer risk and regulates various physiological functions. We hypothesized that 1,25(OH)2 D3 could be associated with the expression and activity of Na+ /H+ exchanger isoform 1 (NHE1) of Lewis lung cancer cells, thus regulating glycolysis as well as migration by actin reorganization. Followed by online public data analysis, Vitamin D3 receptor, the receptor of 1,25(OH)2 D3 has been proved to be abundant in lung cancers. We demonstrated that 1,25(OH)2 D3 treatment suppressed transcript levels, protein levels, and activity of NHE1 in LLC cells. Furthermore, 1,25(OH)2 D3 treatment resets the metabolic balance between glycolysis and OXPHOS, mainly including reducing glycolytic enzymes expression and lactate production. In vivo experiments showed the inhibition effects on tumor growth as well. Therefore, we concluded that 1,25(OH)2 D3 could amend the NHE1 function, which leads to metabolic reprogramming and cytoskeleton reconstruction, finally inhibits the cell migration.
Collapse
Affiliation(s)
- Hong Chen
- Wuxi Medical School, Jiangnan University, Wuxi, People's Republic of China
| | - Mei-Zhen Zhu
- Wuxi Medical School, Jiangnan University, Wuxi, People's Republic of China
| | - Xi-Ting Wang
- Wuxi Medical School, Jiangnan University, Wuxi, People's Republic of China
| | - Min Ai
- Wuxi Medical School, Jiangnan University, Wuxi, People's Republic of China
- Laboratory Animal Center of Shanghai Jiao Tong University, Shanghai, People's Republic of China
| | - Shuang-Shuang Li
- Wuxi Medical School, Jiangnan University, Wuxi, People's Republic of China
- Shanghai Seventh People's Hospital, Shanghai, People's Republic of China
| | - Ming-Yu Wan
- Wuxi Medical School, Jiangnan University, Wuxi, People's Republic of China
| | - Pei-Yao Wang
- Wuxi Medical School, Jiangnan University, Wuxi, People's Republic of China
| | - Wei-Wei Cai
- Wuxi Medical School, Jiangnan University, Wuxi, People's Republic of China
| | - Bao Hou
- Wuxi Medical School, Jiangnan University, Wuxi, People's Republic of China
| | - Fei Xu
- Wuxi Medical School, Jiangnan University, Wuxi, People's Republic of China
| | - Florian Lang
- Department of Physiology, University of Tübingen, Tübingen, Germany
| | - Li-Ying Qiu
- Wuxi Medical School, Jiangnan University, Wuxi, People's Republic of China
| | - Yue-Tao Zhou
- Wuxi Medical School, Jiangnan University, Wuxi, People's Republic of China
| |
Collapse
|
2
|
SLC9A1 Binding mTOR Signaling Pathway-Derived Risk Score Predicting Survival and Immune in Clear Cell Renal Cell Carcinoma. JOURNAL OF ONCOLOGY 2023. [DOI: 10.1155/2023/3937352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Objective. Clear cell renal cell carcinoma (ccRCC) is one of the common renal cell carcinomas (RCC) with a high risk of recurrence. Considering that SLC9A1 is involved in various cellular physiological processes and probably mediates the course of mTOR signaling in tumors, this study constructed a risk model for SLC9A1 combined with mTOR signaling in ccRCC, aiming at better predicting the prognosis of patients. Methods. ccRCC expression matrices were downloaded from TCGA and ICGC databases to compare the expression of SLC9A1 in TCGA, and qRT-PCR was adopted to validate the SLC9A1 expression in different RCC cells and normal kidney cells. The CIBERSORT and ESTIMATE algorithms were used to assess samples for immunity. mTOR signaling-associated genes were downloaded from the KEGG website, and then the genes were adopted to screen genes associated with SLC9A1 expression and mTOR signaling pathway colleagues, based on which univariate COX regression and lasso regression Cox analyses were conducted to construct a ccRCC prognostic risk model. ROC curves and nomograms were used to assess the validity of the models. Results. ccRCC tumor samples showed lower SLC9A1 expression than normal samples, as also evidenced by qRT-PCR. The SLC9A1 expression was highly correlated with tumor immunity. Totally, 564 key genes associated with both SLC9A1 expression and mTOR signaling were screened out, and the risk model consisting of 11 gene signatures was constructed in ccRCC based on the 564 genes. Since patients at a high risk had poorer survival outcomes, the high-risk group presented poorer immunotherapy outcomes. Moreover, a higher clinical grade of patients suggested a higher risk score. The risk score can serve as one independent prognostic factor for the prognosis prediction of ccRCC patients. Conclusion. An extremely promising prognostic indicator for ccRCC based on SLCA9A1 and mTOR signaling has been constructed to provide reference for clinical treatment.
Collapse
|
3
|
Console L, Scalise M. Extracellular Vesicles and Cell Pathways Involved in Cancer Chemoresistance. Life (Basel) 2022; 12:life12050618. [PMID: 35629286 PMCID: PMC9143651 DOI: 10.3390/life12050618] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2022] [Revised: 04/15/2022] [Accepted: 04/16/2022] [Indexed: 02/07/2023] Open
Abstract
Chemoresistance is a pharmacological condition that allows transformed cells to maintain their proliferative phenotype in the presence of administered anticancer drugs. Recently, extracellular vesicles, including exosomes, have been identified as additional players responsible for the chemoresistance of cancer cells. These are nanovesicles that are released by almost all cell types in both physiological and pathological conditions and contain proteins and nucleic acids as molecular cargo. Extracellular vesicles released in the bloodstream reach recipient cells and confer them novel metabolic properties. Exosomes can foster chemoresistance by promoting prosurvival and antiapoptotic pathways, affecting cancer stem cells and immunotherapies, and stimulating drug efflux. In this context, a crucial role is played by membrane transporters belonging to ABC, SLC, and P-type pump families. These proteins are fundamental in cell metabolism and drug transport in either physiological or pathological conditions. In this review, different roles of extracellular vesicles in drug resistance of cancer cells will be explored.
Collapse
Affiliation(s)
- Lara Console
- Correspondence: (L.C.); (M.S.); Tel.: +39-0984-492919 (L.C.); +39-0984-492938 (M.S.)
| | | |
Collapse
|